0001209191-22-014626.txt : 20220302 0001209191-22-014626.hdr.sgml : 20220302 20220302152000 ACCESSION NUMBER: 0001209191-22-014626 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220228 FILED AS OF DATE: 20220302 DATE AS OF CHANGE: 20220302 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Shacham Sharon CENTRAL INDEX KEY: 0001588438 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36167 FILM NUMBER: 22703022 MAIL ADDRESS: STREET 1: C/O KARYOPHARM THERAPEUTICS INC. STREET 2: 85 WELLS AVENUE, SECOND FLOOR CITY: NEWTON STATE: MA ZIP: 02459 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Karyopharm Therapeutics Inc. CENTRAL INDEX KEY: 0001503802 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 263931704 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 85 WELLS AVENUE STREET 2: SECOND FLOOR CITY: NEWTON STATE: MA ZIP: 02459 BUSINESS PHONE: 617-658-0600 MAIL ADDRESS: STREET 1: 85 WELLS AVENUE STREET 2: SECOND FLOOR CITY: NEWTON STATE: MA ZIP: 02459 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-02-28 0 0001503802 Karyopharm Therapeutics Inc. KPTI 0001588438 Shacham Sharon C/O KARYOPHARM THERAPEUTICS INC. 85 WELLS AVENUE NEWTON MA 02459 0 1 0 0 Chief Scientific Officer Common Stock 2022-02-28 4 S 0 6226 10.2375 D 898131 D Common Stock 2022-02-28 4 A 0 21000 0.00 A 719983 I By Spouse Common Stock 2022-02-28 4 S 0 6226 10.2375 D 713757 I By Spouse Stock Option (right to buy) 10.33 2022-02-28 4 A 0 27000 0.00 A 2032-02-27 Common Stock 27000 27000 I By Spouse This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person. Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $10.24 to $10.35, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Represents the award of restricted stock units ("RSUs") to the spouse of the reporting person pursuant to the Karyopharm Therapeutics Inc. 2013 Stock Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in four equal annual installments beginning February 28, 2023. This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the spouse of the reporting person. This option was granted to the spouse of the reporting person on February 28, 2022 pursuant to the Plan. The shares underlying this option vest as to 25% of the shares on February 28, 2023, with the remaining 75% vesting in 36 equal monthly installments thereafter. /s/ Nancy Smith as Attorney-in-Fact for Sharon Shacham 2022-03-02